[Toxicity and radioprotective properties of 1,3-oxazine and 1,3-thiazine derivatives]. 1979

T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova

Toxicity and radioprotective properties of 18 derivatives of oxazine and thiazine with a varying degree of the cycle saturation were studied in experiments on mice. Monotypic regularity in variations of their toxic properties relative to the chemical structure was noted. 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine exerted a pronounced radioprotective action.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008297 Male Males
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D005720 Gamma Rays Penetrating, high-energy electromagnetic radiation emitted from atomic nuclei during NUCLEAR DECAY. The range of wavelengths of emitted radiation is between 0.1 - 100 pm which overlaps the shorter, more energetic hard X-RAYS wavelengths. The distinction between gamma rays and X-rays is based on their radiation source. Gamma Wave,Gamma Radiation,Nuclear X-Rays,Radiation, Gamma,X-Rays, Nuclear,Gamma Radiations,Gamma Ray,Gamma Waves,Nuclear X Rays,Nuclear X-Ray,Ray, Gamma,Wave, Gamma,Waves, Gamma,X Rays, Nuclear,X-Ray, Nuclear
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013843 Thiazines
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
October 2022, ChemistryOpen,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
January 1964, Acta - Unio Internationalis Contra Cancrum,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
January 1963, Advances in heterocyclic chemistry,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
June 1974, Journal of radiation research,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
January 1970, Archivum immunologiae et therapiae experimentalis,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
January 1971, Archivum immunologiae et therapiae experimentalis,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
January 1972, Archivum immunologiae et therapiae experimentalis,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
January 1978, Archivum immunologiae et therapiae experimentalis,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
December 2009, The Journal of pharmacy and pharmacology,
T Iu Il'iuchenok, and L M Frigidova, and K S Shadurskiĭ, and V P Lepekhin, and L A Ignatova
September 1963, Journal of medicinal chemistry,
Copied contents to your clipboard!